Collaboration, License, and Other Agreements - Sanofi, Immuno-Oncology Narrative (Details) - USD ($) $ in Millions		1 Months Ended	3 Months Ended		9 Months Ended
	Jul. 01, 2022	Jul. 31, 2022	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Disaggregation of Revenue [Line Items]
Revenue milestones			$ 2,936.2	$ 3,452.8	$ 8,758.5	$ 11,120.0
Sanofi
Disaggregation of Revenue [Line Items]
Up-front payment to collaborating party		$ 900.0
Sanofi Collaboration Agreement, Immuno-oncology
Disaggregation of Revenue [Line Items]
Royalty payment to collaborating party, percentage of net product sales		11.00%
Other liabilities			0.0		$ 0.0		$ 276.1
Sanofi Collaboration Agreement, Immuno-oncology | Amended IO Discovery Agreement | Other operating income
Disaggregation of Revenue [Line Items]
Cumulative catch-up adjustment to revenue, change in estimate of transaction price			$ 66.9
Sanofi Collaboration Agreement, Immuno-oncology | Regulatory Milestone | Sanofi
Disaggregation of Revenue [Line Items]
Revenue milestones		$ 100.0
Sanofi Collaboration Agreement, Immuno-oncology | Sales-Based Milestones | Sanofi
Disaggregation of Revenue [Line Items]
Revenue milestones		$ 100.0
Sanofi Collaboration Agreement, Amended and Restated Immuno-oncology License and Collaboration Agreement
Disaggregation of Revenue [Line Items]
Royalty payment to collaborating party, percentage of net product sales	0.50%
Remaining performance obligation	$ 35.0
Other liabilities	$ 241.0